Paulo Santos seem to be somewhat bullish, but share some of the same concerns regarding the management's straightforwardness that many shareholders have.
Hopefully these shareholder concerns are brought to shame after the company's Q2 earnings report....and hopefully all shareholders of Musclepharm will stop being ambivalent about the company forever after.